Objective To study the effects of combined leflunomide and cozaar therapy on IgA nephropathy. Methods Forty patients with IgA nephropathy diagnosed by renal biopsy were randomly divided into two groups: cozaar (100 mg/d) treated group and leflunomide(20mg/d) plus cozaar treated group. The changes in proteinuria and serum creatinine were observed. Results After 1 month treatment by the two methods, the level of proteinuria decreased significantly ［(0.92±0.53) vs (1.28±0.99)］（P <0.05）in all.After 3 and 6 months of treatment , the level of proteinuria in combined leflunomide and cozaar therapy group was lower than that in cozaar therapy group（P<0.05）. Conclusions Combined leflunomide and cozaar therapy reduces 24 h urine proteinuria and protects renal function in patients with IgA nephropathy.
Key words
leflunomide /
cozaar /
IgA nephropathy
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
［1］刘洪涛，陈香美，汤力,等.尿激酶联合苯那普利治疗IgA肾病的随访对照研究［J］.中华肾脏病杂志，2003，19（4）：199-204.
［2］张馨，黎磊石，孙骅,等.不同类型IgA肾病的流行病学及临床特点分析［J］.肾脏病与透析肾移植杂志，2006，15（4）：305-309.
［3］张爱平，张磊，王艳侠，等.来氟米特治疗IgA肾病64例［J］．中华肾脏病杂志，2004，20(3)：176-177．
［4］张杰，何俊，李正良，等．来氟米特治疗 IgA肾病的临床研究［J］.中国实用内科杂志，2005，25(7)：628-630．
［5］傅鹏，于光，许静．来氟米特联合激素延缓进展型IgA肾病肾功能减退的临床研究［J］.临床内科杂志，2006,23(11)：731-733．
［6］张欣洲，何永成，罗琼,等．来氟米特治疗IgA肾病的多中心临床对照研究［J］.中国实用内科杂志,2008,28(2)：110-112 ．
［7］Reich H N,Troyanov S,Scholey J W, et al.Remission of proteinuria improves prognosis in IgA Nephropathy［J］. J Am Soc Nephrol,2007,18(12):3177.
［8］石晓云，陈香美，刘述文,等.血管紧张素转换酶抑制剂对IgA肾病的疗效及影响因素分析［J］.中华内科杂志，2002，41（6）：399-402.
［9］Coppo R，Amore A，Gianoglio B，et al.Angiotensin Ⅱ local hyperreactivity in the progression of IgA nephropathy［J］.Am J kidney Dis，1993，21:593-602.
［10］Cherwinski H M，Byars N. Leflunomide interferes with pyrimidine nucleotide biosynthesis［J］. Inflamm Res,1995,44(8):317.
［11］何雪晴，邢昌赢，庄凌,等.来氟米特对被动型Heymann肾炎大鼠肾组织WT-1表达的影响［J］.江苏医药，2007，33（2）：171-174.
［12］Pavenstadt H， Kriz W， Kretzler M．Cell biology of the glomerular podocyte［J］．Physiol Rev,2003,83(1):253-307．
［13］Charles E P，Stewart F，Colin G M．Murine Denys- Drash syndrome: evi dence of podocyte de-differentiation and systemic mediation of glomerul- osclerosis［J］．Human Molecular Genetics，2003，12 (18)：2379 - 2394．
［14］Lou T，Wang C，Chen Z，et al.Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy［J］. Nephrology , 2006,11(2):113.
PDF(413 KB)
